UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000054165
Receipt number R000061853
Scientific Title A verification study for the suppressive effect on the elevation of blood glucose level by continuous consumption of test food: a randomized, placebo-controlled, double-blind, crossover comparison study
Date of disclosure of the study information 2024/04/16
Last modified on 2024/04/16 11:00:14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A verification study for the suppressive effect on the elevation of blood glucose level by continuous consumption of test food: a randomized, placebo-controlled, double-blind, crossover comparison study

Acronym

A verification study for the suppressive effect on the elevation of blood glucose level by continuous consumption of test food: a randomized, placebo-controlled, double-blind, crossover comparison study

Scientific Title

A verification study for the suppressive effect on the elevation of blood glucose level by continuous consumption of test food: a randomized, placebo-controlled, double-blind, crossover comparison study

Scientific Title:Acronym

A verification study for the suppressive effect on the elevation of blood glucose level by continuous consumption of test food

Region

Japan


Condition

Condition

Healthy Japanese

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To verify the effect of continuous consumption of the test food on the suppression of elevated blood glucose levels.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

1. The maximum blood concentration (Cmax) of the glucose at four weeks after consumption (4w)

2. The incremental area under the curve (IAUC) of the glucose at 4w

Key secondary outcomes

1. The total AUC (TAUC), delta Cmax, and the time to maximum blood concentration (Tmax) of the glucose at 4w

2. IAUC and Cmax of the insulin levels at 4w

3. The measured values of the glucose and insulin levels at 0, 30, 60, 90, and 120 minutes after consumption of the carbohydrate load, and the amount of changes of glucose from 0 minute

4. Homeostasis model assessment of insulin resistance (HOMA-IR) at 4w


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment



Intervention

No. of arms

2

Purpose of intervention

Educational,Counseling,Training

Type of intervention

Food

Interventions/Control_1

Duration: Four weeks
Test food:
< Test 1> Capsule containing plant extract
< Test 2> Placebo capsule

*The intervention sequence is Test 1 to Test 2.
*Washout period is for four weeks and more.

Interventions/Control_2

Duration: Four weeks
Test food:
<Test 1> Placebo capsule
< Test 2> Capsule containing plant extract

*The intervention sequence is Test 1 to Test 2.
*Washout period is for four weeks and more.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

64 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Japanese

2. Men or women

3. Individuals aged between 20 and 64

4. Healthy individuals

5. Individuals whose fasting blood glucose level is >=70 and <126 mg/dL, whose blood glucose level at 120 minutes after consumption of a carbohydrate load (225 mL Trelan-G (75 g glucose)) is <200 mg/dL, and whose Cmax of the glucose after consumption of a carbohydrate load (225 mL Trelan-G (75 g glucose)) is >=140 mg/dL at screening (before consumption; Scr)

Key exclusion criteria

1. Individuals who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction

2. Individuals who have a pacemaker or an implantable cardioverter defibrillator (ICD)

3. Individuals who are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases

4. Individuals who are taking "Foods for Specified Health Uses" or "Foods with Functional Claims"

5. Individuals who are taking or using medications (including herbal medicines) and supplements

6. Individuals who are allergic to medicines and/or foods related to the test product, particularly who show allergic reactions to gelatin, beef, ragweed, chrysanthemum, marigold and/or daisy

7. Individuals who are pregnant, lactating, or planning to become pregnant during this study

8. Individuals who have been enrolled in other clinical studies within the last 28 days before the agreement to participate in this study or plan to participate another study during this study

9. Individuals who are judged as ineligible to participate in this study by the physician

Target sample size

6


Research contact person

Name of lead principal investigator

1st name Tsuyoshi
Middle name
Last name Takara

Organization

Medical Corporation Seishinkai, Takara Clinic

Division name

Director

Zip code

141-0022

Address

9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan

TEL

03-5793-3623

Email

t-takara@takara-clinic.com


Public contact

Name of contact person

1st name Naoko
Middle name
Last name Suzuki

Organization

ORTHOMEDICO Inc.

Division name

R&D Department

Zip code

112-0002

Address

2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan

TEL

03-3818-0610

Homepage URL


Email

nao@orthomedico.jp


Sponsor or person

Institute

ORTHOMEDICO Inc.

Institute

Department

Personal name



Funding Source

Organization

ITO EN, LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

Medical Corporation Seishinkai, Takara Clinic

Nerima Medical Association, Minami-machi Clinic

Name of secondary funder(s)



IRB Contact (For public release)

Organization

The ethical committee of the Takara Clinic, Medical Corporation Seishinkai

Address

9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan

Tel

03-5793-3623

Email

IRB@takara-clinic.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)

南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)


Other administrative information

Date of disclosure of the study information

2024 Year 04 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2024 Year 04 Month 10 Day

Date of IRB

2024 Year 04 Month 10 Day

Anticipated trial start date

2024 Year 04 Month 16 Day

Last follow-up date

2024 Year 09 Month 22 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2024 Year 04 Month 16 Day

Last modified on

2024 Year 04 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000061853


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name